Organic Process Research & Development 1998, 2, 203−207
Lecture Transcripts
Independent Synthesis and Fate Studies of Impurities in Process Intermediates
of the Anti-AIDS Drug d4T
Jayachandra P. Reddy,* J. Gregory Reid, Deborah A. Renner, Sandra L. Quinlan, Douglas G. Weaver,†
Bang-Chi Chen, and Derron R. Stark
Chemical DeVelopment Laboratories, Technical Operations, Bristol-Myers Squibb Company, P.O. Box 4755,
Syracuse, New York 13221-4755
Qi Gao‡
Analytical Research, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, 5 Research Parkway,
Wallingford, Connecticut 06492
Scheme 1
Abstract:
Impurities in isolated intermediates in a process to prepare d4T
were identified, independently synthesized, and then taken
through the process to determine their ultimate fate. Some of
the products from these fate studies were also independently
synthesized and used in the validation of impurity assay
methods.
Introduction
d4T (stavudine, Zerit) is currently being marketed for the
treatment of AIDS in the United States and other countries.
Several syntheses of d4T have appeared in the literature.1,2
Among them is one route that was developed by us recently
for the production of d4T from 5-methyluridine (5-MU).2
During the initial scale-up of this new process (Scheme 1),
the levels of some impurities in isolated intermediates were
observed to increase. Investigations into the causes of the
higher levels revealed that these increases were generally
due to the longer processing times that were required on
larger scale, although in some cases there were other
* Phone: (315) 432-2414. Fax: (315) 432-4854. E-mail: jreddy@
usccmail.uscc.bms.com.
† Chemical Development Analytical Services (CDAS).
contributing factors. Independent synthesis of the impurities
not only confirmed the structure assignments but also
provided samples to carry out fate studies. In addition,
samples of observed impurities and potential impurities were
used to validate impurity assay methods.
‡ Correspondence regarding X-ray crystallography should be addressed to this
author.
(1) For recent syntheses of d4T see: (a) McDonald, F. E.; Gleason, M. M. J.
Am. Chem. Soc. 1996, 118, 6648. (b) Clive, D. L. J.; Wickens, P. L.; Sgarbi,
P. W. M. J. Org. Chem. 1996, 61, 7426. (c) Mustafin, A. G.; Gataullin, R.
R.; Spirikhin, L. V.; Abdrakhmanov, I. B.; Tolstikov, G. A. Zh. Org. Khim.
1996, 32, 1842. (d) Shiragami, H.; Ineyama, T.; Uchida, Y.; Izawa, K.
Nucleosides Nucleotides 1996, 15, 47. (e) Becouarn, S.; Czernecki, S.;
Valery, J.-M. Nucleosides Nucleotides 1995, 14, 1227. (f) Larsen, E.;
Kofoed, T.; Pedersen, E. B. Synthesis 1995, 1121. (g) Niihata, S.; Kuno,
H.; Ebata, T.; Matsushita, H. Bull. Chem. Soc. Jpn. 1995, 68, 2327. (h)
Lipshutz, B. H.; Stevens, K. L.; Lowe, R. F. Tetrahedron Lett. 1995, 36,
2711. (i) Luzzio, F. A.; Menes, M. E. J. Org. Chem. 1994, 59, 7267. (j)
Jung, M. E.; Gardiner, J. M. Tetrahedron Lett. 1992, 33, 3841. (k) Vargeese,
C.; Abushanab, E. Nucleosides Nucleotides 1992, 11, 1549. See also ref 2
and references therein.
Results and Discussion
The only significant process impurity in the first step (5-
MU f 1, Scheme 1) of this synthesis is 5′-chloro-5′-deoxy-
3′-O-(methylsulfonyl)-2,2′-anhydro-5-methyluridine, 3 (see
eq 1), which is presumably formed from chloride displace-
ment of the primary methylsulfonyl ester at C-5′ during the
reaction. Independent synthesis of chloride 3 was easily
accomplished by reaction of 1 with lithium chloride in DMF
(2) Chen, B.-C.; Quinlan, S. L.; Stark, D. R.; Reid, J. G.; Audia, V. H.; George,
J. G.; Eisenreich, E.; Brundidge, S. P.; Racha, S.; Spector, R. H. Tetrahedron
Lett. 1995, 36, 7957.
S1083-6160(97)00126-6 CCC: $15.00 © 1998 American Chemical Society and Royal Society of Chemistry
Published on Web 04/17/1998
Vol. 2, No. 3, 1998 / Organic Process Research & Development
•
203